This website uses cookies to enhance the user experience.
PHARMAQ ANALYTIQ AS

PHARMAQ ANALYTIQ AS982 749 042

Research
Limited company
Thormøhlens gate 53D 5006 BERGEN, Norge

PHARMAQ ANALYTIQ AS

PHARMAQ Analytiq applies targeted research and effective analyses with the aim of safeguarding fish health and welfare in the aquaculture sector

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Links

Organization

Chairman of the board
Years since formation
24 years
since Dec 18, 2000
Type
Limited company
VAT registered
Yes
Number of employees
54

Ownership

Number of shares and share classes
11,000
1 share class
Total number of shareholders
2
1 company, 1 person

Financials

Total operating income 2023
86,743,312
NOK
Annual total result 2023
-536,577
NOK
Total equity 2023
20,325,719
NOK
Last update: Dec 5, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Chairman-
Deputy Chair-
Board Member-

Others

NameRoleShares
K
KPMG AS
Auditor-
Last update: Apr 13, 2023

Ownership

Company shareholders

NameShare classNumber of sharesShare
Ordinary shares
10,000
90.91 %
P
PHARMAQ ANALYTIQ AS
Ordinary shares
1,000
9.09 %

Shares owned by the PHARMAQ ANALYTIQ AS

NameShare classNumber of sharesShare
P
PHARMAQ ANALYTIQ AS
Ordinary shares
1,000
9.09 %
Last update: May 24, 2024

Financials

in NOK

Summary

Year202320222021
Total operating income
86,743,312
78,755,537
82,603,554
Annual Total Result
-536,577
-4,847,241
-2,989,021
Total assets
40,398,097
50,285,253
57,211,840
Total liabilities
20,072,378
29,422,956
36,955,940
Total equity
20,325,719
20,862,297
20,255,900

P&L

Year202320222021
Total operating income
86,743,312
78,755,537
82,603,554
Total operating costs
86,769,906
84,654,011
86,234,596
Operating result
-26,594
-5,898,474
-3,631,042
Financial income/costs
-673,728
-480,965
-229,591
Profit before tax
-700,322
-6,379,439
-3,860,633
Total tax & extraordinary income/cost
-163,745
-1,532,198
-871,612
Annual Total Result
-536,577
-4,847,241
-2,989,021

Balance overview

Year202320222021
Total fixed assets
21,525,375
23,521,895
26,919,159
Total current assets
18,872,722
26,763,358
30,292,681
Total assets
40,398,097
50,285,253
57,211,840
Short term debt
19,851,772
29,001,736
36,540,727
Long term debt
220,606
421,220
415,213
Total liabilities
20,072,378
29,422,956
36,955,940
Contributed capital
13,041,284
13,041,284
7,587,646
Retained earnings
7,284,435
7,821,013
12,668,254
Total equity
20,325,719
20,862,297
20,255,900
Total equity and liabilities
40,398,097
50,285,253
57,211,840

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology